文献速递免疫规划传染病防控与疫情报告

2024-2025年新冠疫苗在美国儿童中的有效性——VISION,2024年8月29日至2025年9月2日

Effectiveness of 2024-2025 COVID-19 Vaccines in Children in the United States - VISION, August 29, 2024-September 2, 2025.
PubMed 文献 · MMWR Morb Mortal Wkly Rep · 2025-12-11

研究采用检测阴性病例对照设计,评估2024-2025年新冠疫苗对9月龄至17岁免疫功能正常儿童新冠相关急诊或紧急护理就诊的保护效果,接种后7-179天内9月龄至4岁儿童疫苗有效性为76%(95%CI=58%-87%),5-17岁儿童为56%(95%CI=35%-70%)。

要点

  • 9月龄至4岁儿童接种后7-179天,疫苗对新冠相关急诊或紧急护理就诊的有效性为76%(95%CI=58%-87%)。
  • 5-17岁儿童和青少年接种后7-179天,疫苗对新冠相关急诊或紧急护理就诊的有效性为56%(95%CI=35%-70%)。
  • 与未接种2024-2025年剂量相比,接种该剂量可为儿童提供额外保护。

核心结论

  • 接种2024-2025年新冠疫苗剂量可为儿童提供针对新冠相关急诊或紧急护理就诊的额外保护, compared with no 2024-2025 dose。

研究设计与样本

  • 采用检测阴性病例对照设计,估算2024-2025年新冠疫苗的有效性(VE)。
  • 研究纳入美国CDC资助的VISION网络(基于电子健康记录的多站点网络,覆盖九个州)中9月龄至4岁儿童及5-17岁儿童和青少年。
  • 研究对象为免疫功能正常者,评估时间段为2024年8月29日至2025年9月2日。
  • 结局为新冠相关急诊或紧急护理(ED/UC)就诊,评估接种后7-179天内的疫苗有效性。

主要发现

  • 9月龄至4岁儿童接种后7-179天内,针对新冠相关ED/UC就诊的VE为76%(95%CI=58%-87%)。
  • 5-17岁儿童和青少年接种后7-179天内,针对新冠相关ED/UC就诊的VE为56%(95%CI=35%-70%)。
  • 2023年9月至2024年8月期间,美国18岁以下儿童和青少年中约发生38,000例新冠相关住院,率约为53/10万儿童,范围从6月龄以下儿童的600/10万到5-17岁儿童和青少年的21/10万。

关键数值与推荐

  • 2024年6月27日,免疫实践咨询委员会(ACIP)推荐所有≥6月龄者接种2024-2025年新冠疫苗,该疫苗针对Omicron JN.1及JN.1衍生亚系。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

During September 2023-August 2024, approximately 38,000 COVID-19-associated hospitalizations occurred among children and adolescents aged <18 years in the United States, a rate of approximately 53 per 100,000 children, ranging from 600 per 100,000 children aged <6 months to 21 per 100,000 children and adolescents aged 5-17 years. On June 27, 2024, the Advisory Committee on Immunization Practices recommended that all persons aged ≥6 months receive a 2024-2025 COVID-19 vaccine, which targeted Omicron JN.1 and JN.1-derived sublineages. Investigators used a test-negative case-control design to estimate vaccine effectiveness (VE) of 2024-2025 COVID-19 vaccines against COVID-19-associated emergency department or urgent care (ED/UC) visits during August 29, 2024-September 2, 2025, among immunocompetent children aged 9 months-4 years and children and adolescents aged 5-17 years in the CDC-funded Virtual SARS-CoV-2, Influenza, and Other respiratory viruses Network (VISION), a multisite electronic health record-based network in nine states. Among children aged 9 months-4 years, VE against COVID-19-associated ED/UC visits was estimated at 76% (95% CI = 58%-87%) during the first 7-179 days after vaccination. Among children and adolescents aged 5-17 years, VE against COVID-19-associated ED/UC visits was an estimated 56% (95% CI = 35%-70%) during the first 7-179 days after vaccination. These findings suggest that vaccination with a 2024-2025 COVID-19 vaccine dose provided children with additional protection against COVID-19-associated ED/UC encounters compared with no 2024-2025 dose.

来源:MMWR Morb Mortal Wkly Rep,查看原文。版权归原作者所有。

引用

  1. Irving SA, Rowley EAK, Chickery S, et al. Effectiveness of 2024-2025 COVID-19 Vaccines in Children in the United States - VISION, August 29, 2024-September 2, 2025. MMWR Morb Mortal Wkly Rep. 2025. PMID: 41379943. doi:10.15585/mmwr.mm7440a1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。